← Back

Borregaard ASA

0QB7.LSENOK
150.30-19.3%1Y · NOK

Borregaard ASA develops, produces, and markets specialized biochemicals and biomaterials in Norway, the rest of Europe, Asia, the United States, and internationally. It operates in three segments: BioSolutions, BioMaterials, and Fine Chemicals. BioSolutions develops, produces, and sells biopolymers and biovanillin derived from lignin for agrochemicals, batteries, industrial binders, and construction, as well as for flavor and fragrance companies and the food and beverage industry. BioMaterials develops, produces, and sells specialty cellulose used as a raw material in cellulose ethers, cellulose acetate, and other specialty products, along with cellulose fibrils for industrial applications. Fine Chemicals supplies fine chemical intermediates for contrast agents and advanced bioethanol. The company was incorporated in 2012 and is headquartered in Sarpsborg, Norway.

Price · split & dividend adjusted
News & notes moving 0QB7.LSE
Norway
Synthetic Biology (non-pharma)▲

Borregaard Refinances With NOK 1,500 Million Sustainability-Linked Credit Facilities

Borregaard has arranged new sustainability-linked multicurrency revolving credit facilities totaling NOK 1,500 million with three banks, replacing existing arrangements that were approaching maturity. The facilities secure continued access to committed funding, with loan terms tied to environmental and safety targets including greenhouse gas emission cuts and workplace safety measures. The company operates in the chemicals sector, focusing on specialized biochemicals and biomaterials for customers across Europe, Asia, the United States, and other regions. The refinancing keeps Borregaard's debt profile aligned with its buyback-and-earnings-reset narrative, tying borrowing costs to how effectively it runs its mills rather than to market rates alone. With profit margins recently weaker than a year ago, the flexible general-purpose credit leaves room to balance capacity upgrades against authorized share repurchases without overstretching the balance sheet.
About megatrends
Synthetic Biology (non-pharma) › Bio-Based Materials & Industrial Chemicals Capital
Critical Materials & Supply Chain › Specialty Chemicals & Industrial Gases Capital
0QB7.LSE · Capital · Positive Borregaard arranged NOK 1,500 million in new sustainability-linked revolving credit facilities, securing committed funding and refinancing maturing debt.
Read original ↗
Simply Wall St·2dRead more →
0QB7.LSE▼

Borregaard reports EBITDA of NOK 515 million in second quarter

Borregaard ASA reported EBITDA of NOK 515 million in the second quarter of 2026, slightly down from NOK 522 million a year earlier, as higher sales volume in BioSolutions was offset by increased energy costs, negative currency effects, and a less favourable product mix. Operating revenues rose to NOK 2,114 million from NOK 2,045 million, with improved results in BioMaterials and Fine Chemicals but a decline in BioSolutions. The company recorded a NOK 337 million impairment on its investment in Alginor ASA and NOK 30 million in other expenses for ground stabilisation at its Sarpsborg site, leading to a loss before tax of NOK 45 million compared with a profit of NOK 326 million in the prior-year period. Excluding those items, earnings per share were NOK 2.35. Borregaard is implementing a cost improvement programme targeting annual savings of NOK 150 million, with full effect expected from 2028.
0QB7.LSE · Capital · Negative EBITDA slightly down, impairment and other expenses lead to loss before tax, though cost programme announced.
Alginor ASA · Capital · Negative Borregaard recorded a NOK 337 million impairment on its investment in Alginor ASA.
Read original ↗
GlobeNewswire·87dRead more →